Literature DB >> 30255519

Pre-Operative chemotherapy response assessed by contrast-enhanced MRI can predict the prognosis of Enneking surgical margins in patients with osteosarcoma.

Fangzhou He1, Le Qin2, Qiyuan Bao1, Shizhao Zang1, Qin He1, Shijing Qiu1,3,4, Yuhui Shen1,3, Weibin Zhang1,3.   

Abstract

The method used to evaluate the response of osteosarcoma to preoperative chemotherapy before specimen resection is still unclear. The purpose of this study was to identify factors that contribute to overall survival (OS) and to discuss their roles in making a decision regarding Enneking surgical margins. Patients (109) with pathologically confirmed Enneking stage IIB osteosarcoma were retrospectively analyzed. Univariate and multivariate survival analyses were performed. Patient characteristics and chemotherapy-induced contrast-enhanced MRI changes were considered as potential factors. Changes in the tumor volume and the relative necrosis ratio measured by MRI were independent risk factors predicting the OS of patients who underwent limb-salvage surgery. For those in whom the tumor volume had decreased (VolRatio <1) or the relative necrosis ratio had increased by at least 10% (NecRatioInc ≥0.1), there was no significant difference in OS between Enneking wide and marginal margins. Variables measured by contrast-enhanced MRI could be used to evaluate chemotherapy response and increase the limb-salvage rate.
© 2018 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res. © 2018 Orthopaedic Research Society. Published by Wiley Periodicals, Inc.

Entities:  

Keywords:  MRI; chemotherapy response; extremity; osteosarcoma; surgical margin

Mesh:

Substances:

Year:  2018        PMID: 30255519     DOI: 10.1002/jor.24143

Source DB:  PubMed          Journal:  J Orthop Res        ISSN: 0736-0266            Impact factor:   3.494


  3 in total

1.  A Delta-radiomics model for preoperative evaluation of Neoadjuvant chemotherapy response in high-grade osteosarcoma.

Authors:  Peng Lin; Peng-Fei Yang; Shi Chen; You-You Shao; Lei Xu; Yan Wu; Wangsiyuan Teng; Xing-Zhi Zhou; Bing-Hao Li; Chen Luo; Lei-Ming Xu; Mi Huang; Tian-Ye Niu; Zhao-Ming Ye
Journal:  Cancer Imaging       Date:  2020-01-14       Impact factor: 3.909

2.  Effect of Paclitaxel Combined with Doxorubicin Hydrochloride Liposome Injection in the Treatment of Osteosarcoma and MRI Changes before and after Treatment.

Authors:  Ning Tian; Dongmei Wang; Xiaobao Li; Minghua Xue; Bo Zheng
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-30       Impact factor: 2.650

3.  A Scoring System for Predicting Neoadjuvant Chemotherapy Response in Primary High-Grade Bone Sarcomas: A Multicenter Study.

Authors:  Fangzhou He; Lu Xie; Xin Sun; Jie Xu; Yuan Li; Rong Liu; Kunkun Sun; Danhua Shen; Jin Gu; Tao Ji; Wei Guo
Journal:  Orthop Surg       Date:  2022-08-26       Impact factor: 2.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.